VRTX240802P495000
- 5.49
- -3.08-35.94%
Vertex Pharmaceuticals Newsroom
Canaccord Genuity Maintains Sell on Vertex Pharmaceuticals, Raises Price Target to $376
Vertex Pharmaceuticals Analyst Ratings
CCORF Maintains Vertex Pharmaceuticals(VRTX.US) With Sell Rating, Raises Target Price to $376
Canaccord Genuity Adjusts Price Target on Vertex Pharmaceuticals to $376 From $371
Leerink Partners Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $545
Buy Rating Affirmed for Vertex Pharmaceuticals Amid Promising Pain Management and Cystic Fibrosis Developments
Needham Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $500 From $450, Maintains Buy Rating
Buy Rating Affirmed for Vertex Pharmaceuticals Amid Strategic Acquisition and Strong CF Franchise Outlook
Piper Sandler Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)
Vertex Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Vertex Pharmaceuticals to $480 From $440
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $566 From $500
Vertex Pharmaceuticals Analyst Ratings
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $589 From $577, Maintains Buy Rating